You are here

A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors

Last updated on March 26, 2019

FOR MORE INFORMATION
Study Location
University of Chicago Medical Center
Chicago, Illinois, 60637 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Advanced Solid Tumors
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosis - Dose Escalation Phase: Histologically or cytologically confirmed diagnosis
of advanced solid tumor that is resistant to standard therapy or for which no standard
therapy is available.

- Diagnosis - Dose Expansion Phase: Histologically or cytologically confirmed advanced
RCC with a component of clear cell subtype

- Dose Expansion Phase: at least one measureable lesion as defined by RECIST [Response
Evaluation Criterion in Solid Tumors] version 1.1.

- ECOG [Eastern Cooperative Oncology Group] Performance Status 0 or 1.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Major surgery

- History of or known active seizure disorder, brain metastases, spinal cord
compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal
disease.

- Dose Expansion Phase only: diagnosis of any other malignancy within 2 years prior to
registration.

NCT01999972
Pfizer
Active, not recruiting
A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Advanced Solid Tumors, Metastatic Solid Tumors
NCT03854227
All Genders
18+
Years
Multiple Sites
Advanced Solid Tumors
NCT02997176
All Genders
18+
Years
Multiple Sites
Advanced Solid Tumors
NCT02997163
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now